Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO

Provided By PR Newswire

Last update: Feb 13, 2025

-- Allowed Patent Extends SOLOSEC IP to 2040 with Broad Claims that are Orange Book-listable --

SAN DIEGO, Feb. 13, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/028,838, entitled "Method and Pharmaceutical Composition for Treating or Preventing Trichomoniasis and Uses Thereof." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.